874 Aperçu des actions
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, avec ses filiales, recherche, développe, fabrique et vend des médicaments chinois brevetés et occidentaux, des matières premières chimiques, des médicaments naturels et biologiques, et des intermédiaires de matières premières chimiques en République populaire de Chine et à l'étranger. Plus de détails
Score flocon de neige | |
---|---|
Évaluation | 3/6 |
Croissance future | 1/6 |
Performances passées | 2/6 |
Santé financière | 4/6 |
Dividendes | 3/6 |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Concurrents
Historique des prix et performances
Historique des cours de bourse | |
---|---|
Prix actuel de l'action | HK$18.10 |
Plus haut sur 52 semaines | HK$24.20 |
Plus bas sur 52 semaines | HK$16.62 |
Bêta | 0.59 |
1Variation sur 1 mois | -5.24% |
Variation sur 3 mois | -6.70% |
Variation sur 1 an | -17.16% |
3Variation sur 3 ans | -4.33% |
Variation sur 5 ans | -22.65% |
Évolution depuis l'introduction en bourse | 1,250.75% |
Nouvelles et mises à jour récentes
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Rendement pour les actionnaires
874 | HK Healthcare | HK Marché | |
---|---|---|---|
7D | -3.4% | -3.4% | 0.05% |
1Y | -17.2% | -24.4% | 11.5% |
Rendement vs Industrie: 874 a dépassé le secteur Hong Kong Healthcare qui a rapporté -24.4 % au cours de l'année écoulée.
Rendement vs marché: 874 a sous-performé le marché Hong Kong qui a rapporté 11.5 % au cours de l'année écoulée.
Volatilité des prix
874 volatility | |
---|---|
874 Average Weekly Movement | 6.2% |
Healthcare Industry Average Movement | 8.2% |
Market Average Movement | 9.0% |
10% most volatile stocks in HK Market | 18.9% |
10% least volatile stocks in HK Market | 4.2% |
Cours de l'action stable: 874 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de 874 ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
Fondée | Salariés | PDG | Site web |
---|---|---|---|
1997 | 28,760 | Hong Li | www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, avec ses filiales, recherche, développe, fabrique et vend des médicaments chinois brevetés et occidentaux, des matières premières chimiques, des médicaments naturels et biologiques, et des intermédiaires de matières premières chimiques en République populaire de Chine et au niveau international. La société exerce ses activités par l'intermédiaire des segments Great Southern TCM, Great Commerce, Great Health et Other. Elle est également impliquée dans la vente en gros, la vente au détail, la vente, l'importation et l'exportation de médicaments occidentaux et chinois, d'instruments médicaux, de produits pharmaceutiques, d'équipements médicaux et de produits de santé ; dans la recherche et le développement, la production et la vente de boissons, de produits alimentaires, de produits de santé et d'autres produits ; dans la production et la vente d'aliments préemballés, de produits laitiers, etc. En outre, la société investit dans l'industrie de la santé, comme les services médicaux, la gestion de la santé, l'entretien de la santé, les soins aux personnes âgées, etc., et fournit des services de location et commerciaux, de santé, de publicité, de chargement et de déchargement, ainsi que des services d'entreposage.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Résumé des fondamentaux
874 statistiques fondamentales | |
---|---|
Capitalisation boursière | HK$47.42b |
Bénéfices(TTM) | HK$3.68b |
Recettes(TTM) | HK$82.11b |
8.0x
Ratio P/E0.4x
Ratio P/SLe site 874 est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
874 compte de résultat (TTM) | |
---|---|
Recettes | CN¥76.39b |
Coût des recettes | CN¥63.46b |
Marge brute | CN¥12.93b |
Autres dépenses | CN¥9.50b |
Les revenus | CN¥3.42b |
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) | 2.11 |
Marge brute | 16.92% |
Marge bénéficiaire nette | 4.48% |
Ratio dettes/capitaux propres | 35.5% |
Quelles ont été les performances à long terme de 874?
Voir les performances historiques et les comparaisons